Gabriella Ricciardelli1, Giuseppe Giannaccare2, Antonio Di Zazzo3, Marco Coassin3, Vincenzo Scorcia2, Mario R Romano4,5, Davide Allegrini4, Michela Cennamo6, Marco Antonini3, Federico Bernabei7, Alberto Morelli6, Rita Mencucci6. 1. Department of Ophthalmology, Humanitas Gavazzeni e Castelli, Via Mazzini, Bergamo, Italy. gabriella.ricciardelli01@gmail.com. 2. Department of Ophthalmology, University of Magna Graecia, Catanzaro, Italy. 3. Ophthalmology Complex Unit, Campus Bio-Medico University Hospital, Rome, Italy. 4. Department of Ophthalmology, Humanitas Gavazzeni e Castelli, Via Mazzini, Bergamo, Italy. 5. Department of Biomedical Science, Humanitas University, Via Montalcini, Pieve Emanuele (MI), Italy. 6. Eye Clinic, Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. 7. Ophthalmology Unit, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Abstract
OBJECTIVES: To analyze the effect of the employment of polyvinylpyrrolidone-iodine (PVP-I) 0.6% eye drop on the clinical course of patients affected by Adenoviral Keratoconjunctivitis (AKC). METHODS: Consecutive patients with clinical signs of AKC and positive results of AdenoPlus test were enrolled from four Italian Centres. Patients were randomized to receive: PVP-I 0.6% eye drops four times/daily for 20 days (Group A) or hyaluronate-based tear substitutes four times/daily for 20 days (Group B). Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) Optovue iVue pachymetry map; corneal haze; conjunctival injection and chemosis; subepithelial corneal infiltrates (SEIs); corneal and conjunctival staining and corneal densitometry were recorded at diagnosis and at every follow-up visit. The primary outcome was the resolution time of AKC. RESULTS: Overall, 59 AKC patients (34 for Group A and 25 for Group B) completed the study. Patients of Group A showed a significantly shorter resolution time and lower incidence of SEIs compared to patients of Group B. In particular, SEIs were present at the last visit in 3/34 (8.82%) patients of the Group A vs 11/25 (44%) of the Group B (p = 0.005). Patients of Group A showed a significantly lower incidence of corneal haze compared to patients of Group B (0/34 vs 3/25; p = 0.038). No side effects were reported for both groups. CONCLUSIONS: Although further clinical evaluations are needed, according to our data the use of PVP-I 0.6% eye drop in the setting of AKC reduces the risk of SEIs as well as the resolution time of the disease.
OBJECTIVES: To analyze the effect of the employment of polyvinylpyrrolidone-iodine (PVP-I) 0.6% eye drop on the clinical course of patients affected by Adenoviral Keratoconjunctivitis (AKC). METHODS: Consecutive patients with clinical signs of AKC and positive results of AdenoPlus test were enrolled from four Italian Centres. Patients were randomized to receive: PVP-I 0.6% eye drops four times/daily for 20 days (Group A) or hyaluronate-based tear substitutes four times/daily for 20 days (Group B). Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) Optovue iVue pachymetry map; corneal haze; conjunctival injection and chemosis; subepithelial corneal infiltrates (SEIs); corneal and conjunctival staining and corneal densitometry were recorded at diagnosis and at every follow-up visit. The primary outcome was the resolution time of AKC. RESULTS: Overall, 59 AKC patients (34 for Group A and 25 for Group B) completed the study. Patients of Group A showed a significantly shorter resolution time and lower incidence of SEIs compared to patients of Group B. In particular, SEIs were present at the last visit in 3/34 (8.82%) patients of the Group A vs 11/25 (44%) of the Group B (p = 0.005). Patients of Group A showed a significantly lower incidence of corneal haze compared to patients of Group B (0/34 vs 3/25; p = 0.038). No side effects were reported for both groups. CONCLUSIONS: Although further clinical evaluations are needed, according to our data the use of PVP-I 0.6% eye drop in the setting of AKC reduces the risk of SEIs as well as the resolution time of the disease.
Authors: J Hillenkamp; T Reinhard; R S Ross; D Böhringer; O Cartsburg; M Roggendorf; E De Clercq; E Godehardt; R Sundmacher Journal: Arch Ophthalmol Date: 2001-10
Authors: Jost Hillenkamp; Thomas Reinhard; Rudolf S Ross; Daniel Böhringer; Olaf Cartsburg; Michael Roggendorf; Erik De Clercq; Erhard Godehardt; Rainer Sundmacher Journal: Ophthalmology Date: 2002-05 Impact factor: 12.079
Authors: Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo Journal: Cochrane Database Syst Rev Date: 2022-03-03